0.37
+0.0138(+3.85%)
Currency In USD
| Previous Close | 0.36 |
| Open | 0.36 |
| Day High | 0.38 |
| Day Low | 0.34 |
| 52-Week High | 2.17 |
| 52-Week Low | 0.3 |
| Volume | 543,096 |
| Average Volume | 1.16M |
| Market Cap | 26.9M |
| PE | -0.26 |
| EPS | -1.41 |
| Moving Average 50 Days | 0.46 |
| Moving Average 200 Days | 0.71 |
| Change | 0.01 |
If you invested $1000 in Beyond Air, Inc. (XAIR) since IPO date, it would be worth $126.34 as of January 16, 2025 at a share price of $0.373. Whereas If you bought $1000 worth of Beyond Air, Inc. (XAIR) shares 5 years ago, it would be worth $55.79 as of January 16, 2025 at a share price of $0.373.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Beyond Air to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025
GlobeNewswire Inc.
Jan 06, 2025 1:00 PM GMT
GARDEN CITY, N.Y., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve th
Beyond Cancer Announces Approval by the Israeli Ministry of Health to Conduct a Phase 1b Clinical Trial Utilizing Low Volume Ultra-High Concentration Nitric Oxide (LV UNO) in Combination with Anti-PD-1 Therapy
GlobeNewswire Inc.
Dec 03, 2024 9:05 PM GMT
The Phase 1b study will evaluate LV UNO in unresectable cutaneous or subcutaneous histologically confirmed primary or metastatic solid tumor cancer patients that have progressed or have prolonged stable disease on single agent PD-1 inhibitorsThe prim
Beyond Air Receives CE Mark in Europe for the LungFit® PH System
GlobeNewswire Inc.
Dec 02, 2024 12:30 PM GMT
Indication covers newborn infants with hypoxic respiratory failure and peri- and post-operative pulmonary hypertension to improve right ventricular function in conjunction with heart surgery A $1 million milestone payment is triggered from Asia-Pacif